获取途径

作者

Hong Zhao, Yilei Mao, Hongguang Wang, Aiping Zhou, Zhengqiang Yang, Yue Han, Gong Li, Xinyu Bi, Chunyi Hao, Xiaodong Wang, Jun Zhou, Chaoliu Dai, Feng Wen, Jingdong Zhang, Ruibao Liu, Tao Li, Lei Zhao, Zuoxing Niu, Tianfu Wen, Qiu Li, Hongmei Zhang, Xiaoming Chen, Minshan Chen, Ming Zhao, Yajin Chen, Jun Yu, Jie Shen, Xiangchen Li, Lianxin Liu, Zhiyong Huang, Wei Zhang, Feng Shen, Weiping Zhou, Zhengang Yuan, Jian Zhai, Ningling Ge, Yongjun Chen, Huichuan Sun, Jianqiang Cai

作者单位

Affiliations ¹ Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China. ² Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital PUMC and Chinese Academy of Medical Sciences (CAMS) Beijing China. ³ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China. ⁴ Department of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China. ⁵ Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH) School of Clinical Medicine, Tsinghua University Beijing China. ⁶ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Sarcoma Center Peking University Cancer Hospital & Institute Beijing China. ⁷ Departments of Interventional Oncology Peking University Cancer Hospital & Institute Beijing China. ⁸ Department of Medical Oncology Peking University Cancer Hospital & Institute Beijing China. ⁹ Department of General Surgery Shengjing Hospital of China Medical University Shenyang Liaoning China. ¹⁰ Department of Radiology Shengjing Hospital of China Medical University Shenyang Liaoning China. ¹¹ Medical Oncology Department of Gastrointestinal Cancer Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University Shenyang Liaoning China. ¹² Interventional Radiological Department Harbin Medical University Cancer Hospital Harbin Heilongjiang China. ¹³ Department of General Surgery, Qilu Hospital The Second Hospital of Shandong University Jinan Shandong China. ¹⁴ Department of Hepatobiliary Surgery Shandong Cancer Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Science Jinan Shandong China. ¹⁵ Department of Gastroenterology, Ward 2, Shandong Cancer Hospital and Institute Shandong First Medical University Jinan Shandong China. ¹⁶ Department of Liver Surgery, West China Hospital Sichuan University Chengdu Sichuan China. ¹⁷ Cancer Center, West China Hospital Sichuan University Chengdu Sichuan China. ¹⁸ Department of Clinical Oncology, Xijing Hospital The Air Force Military Medical University Xi'an Shaanxi China. ¹⁹ Department of Interventional Radiology Guangdong Provincial People's Hospital Guangzhou Guangdong China. ²⁰ Department of Liver Surgery Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China. ²¹ Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group Sun Yat-sen University Cancer Center Guangzhou Guangdong China. ²² Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou Guangdong China. ²³ Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China. ²⁴ Department of Oncology The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu China. ²⁵ Hepatobiliary Center The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China. ²⁶ Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China. ²⁷ Hepatic Surgery Center, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China. ²⁸ Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital Second Military Medical University (Naval Medical University) Shanghai China. ²⁹ Department of Oncology, Eastern Hepatobiliary Surgery Hospital Second Military Medical University Shanghai China. ³⁰ Department II of Interventional Radiology Eastern Hepatobiliary Surgery Hospital Shanghai China. ³¹ Department of Hepatic Oncology, Zhongshan Hospital, Liver Cancer Institute and Key Laboratory of Carcinogenesis and Cancer Invasion Fudan University Shanghai China. ³² Department of General Surgery, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China. ³³ Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital Fudan University Shanghai China.

刊名

Cancer innovation

年份

2025

卷号

Vol.4 No.3

页码

e70006

ISSN

2770-9183

关键词

TKI adjuvant therapy downstaging/conversion therapy immunotherapy neoadjuvant therapy.

摘要

Background: Hepatocellular carcinoma is the second leading cause of cancer-related death in China. The rapid progress in systemic therapies has led to the approval of many therapeutic methods that have quickly changed clinical guidelines and practices. Because of the high heterogeneity of HCC, there are still some gaps between the guidelines and real-world clinical practice. The present study surveyed experts in China to investigate the current treatment concepts and clinical practice regarding...更多

Background: Hepatocellular carcinoma is the second leading cause of cancer-related death in China. The rapid progress in systemic therapies has led to the approval of many therapeutic methods that have quickly changed clinical guidelines and practices. Because of the high heterogeneity of HCC, there are still some gaps between the guidelines and real-world clinical practice. The present study surveyed experts in China to investigate the current treatment concepts and clinical practice regarding HCC. Methods: A questionnaire survey on the treatment concepts and clinical practice of HCC was administered to 310 experts with senior professional titles in 2020 and 312 experts in 2021. The results were analyzed and compared. Results: For treating patients with resectable HCC, 28% of hepatobiliary surgeons indicated neoadjuvant therapy, and 7% chose systemic therapy ± locoregional therapy as 1 L therapy in 2021 compared with 20% and 1% in 2020. More experts chose adjuvant treatment within 1 month in 2021 compared with 2020, and 6 months and 12 months were the leading choices for the duration of adjuvant treatment. In 2021, 79% of surgeons and 19% of interventionalists were willing to conduct downstaging/conversion therapy for patients with potentially resectable HCC, and 78% chose tyrosine kinase inhibitors + immunotherapy + locoregional therapy for cases in which R0 resection could not be achieved. For completely unresectable HCC, more experts preferred TKI + IO-based therapy as 1 L therapy in 2021 compared with 2020 . The proportion of experts who indicated TKI + IO-based therapy as 2 L therapy increased from 32% in 2020 to 40% in 2021. Conclusion: The survey results indicated that in 2021, compared with 2020, more experts opted to administer IO + TKI for the treatment of liver cancer, and more experts and patients were willing to participate in clinical research.收起

文献类型

期刊